newsfilter
← Latest News
GlobeNewswire·

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Arcutis Biotherapeutics granted 58,500 restricted stock units (RSUs) & options for 17,000 shares to six newly hired employees.
  • Awards were approved by the Compensation Committee on November 2, 2026, under the 2022 Inducement Plan as a material inducement per Nasdaq Listing Rule 5635(c)(4).
  • RSUs vest over four years with 25 percent vesting annually on each anniversary, contingent on continued employment.
  • Stock options vest over four years, with 25 percent vesting after one year & the remainder in 36 equal monthly installments, subject to continuous employment.
  • Options have a ten-year term & an exercise price of $31.26 per share, matching the Nasdaq closing price on November 2, 2026.
  • Arcutis is a commercial-stage dermatology company developing targeted topicals for chronic inflammatory skin diseases.
Company
Arcutis Biotherapeutics, Inc.
Keywords
Nasdaq:ARQT, Arcutis Biotherapeutics, Inc.